Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

The prostate cancer registry: Patient characteristics, treatments and preliminary outcomes from a large observational study of metastatic castration-resistant prostate cancer (mCRPC)

Date

09 Oct 2016

Session

Poster display

Presenters

Simon Chowdhury

Citation

Annals of Oncology (2016) 27 (6): 243-265. 10.1093/annonc/mdw372

Authors

S. Chowdhury1, A.J. Birtle2, A. Bjartell3, L.A.;. Costa4, S. Feyerabend5, L. Galli6, E. Kalinka-Warzocha7, G. Kramer8, J.P. Maroto Rey9, N. Lumen10, V.B. Matveev11, T. Paiss12, D. Spaeth13, L. Antoni14, E. Klumper15, R. Wapenaar16, E. Lee14

Author affiliations

  • 1 Oncology, Guy's and St. Thomas' Hospital NHS Trust, SE1 9RT - London/GB
  • 2 Rosemere Cancer Centre, Royal Preston Hospital-Lancashire Teaching Hospitals NHS Foundation Trust, PR2 9HT - Preston/GB
  • 3 Dept Of Urology, Skane University Hospital-Lund, SE 205 02 - Malmo/SE
  • 4 Oncology, Hospital de Santa Maria, 1649-035 - Lisbon/PT
  • 5 Urology, Studienpraxis Urologie, 72622 - Nürtingen/DE
  • 6 Oncology, Azienda Ospedaliera Universitaria S.Chiara, 56100 - Pisa/IT
  • 7 Oncology, Kopernik Memory Hospital Lodz, 93-513 - Lodz/PL
  • 8 Department Of Urology, Medizinische Universitaet Wien (Medical University of Vienna), A-1090 - Vienna/AT
  • 9 Oncology, Hospital de la Santa Creu i Sant Pau, 89, 08026 - Barcelona/ES
  • 10 Dept. Of Urology, Gent University Hospital, 9000 - Gent/BE
  • 11 Department Of Urology, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
  • 12 Urologieteam Ulm, Ulm Medical University, 89073 - Ulm/DE
  • 13 Oncology, Centre d’Oncologie de Gentilly, 54000 - Nancy/FR
  • 14 Emea Medical Affairs, Janssen Pharmaceutica, B-2340 - Beerse/BE
  • 15 Oncology, SMS-oncology BV, 1098 - Amsterdam/NL
  • 16 Dept Biostatistics, Janssen-Cilag BV, 5026 RH - Tilburg/NL
More

Resources

Abstract 1414

Background

The Prostate Cancer Registry (NCT02236637) is the first prospective, international, observational study to describe routine management of mCRPC. The registry has enrolled over 3000 patients, with up to 3 years' follow-up. This analysis reports baseline characteristics, treatments and first clinical outcomes in 1374 patients.

Methods

Data collected prospectively from medical records of men with documented mCRPC initiating a new mCRPC treatment or in surveillance (no active treatment; ongoing androgen deprivation and/or bone-targeted therapy allowed). Data and analyses were descriptive.

Results

Median follow-up at database close was 14.2 months (range: 0.2-28.6). Mean age at enrolment was 72.6 years; 55% of patients had a Gleason score ≥ 8 at diagnosis. 58.5% of patients had comorbidities at enrolment, most commonly cardiovascular disorders (51.7%; 41.3% hypertension) and diabetes (15.2%). 876 patients (63.8%) were chemotherapy-naïve at enrolment. During the 12-month observation period, 1191 patients (86.7%) initiated new mCRPC treatment. Descriptive, non-comparative data on previous treatment lines and time to next therapy by first documented treatment received on study are in the table.

Chemotherapy-naïve treatment Chemotherapy-naïve treatment First chemotherapy treatment Post-chemotherapy treatment Post-chemotherapy treatment Post-chemotherapy treatment Post-chemotherapy treatment
First documented treatment received on study (treatments with n ≥ 50) Abiraterone acetate +  prednisone (n = 324) Enzalutamide (n = 53) Docetaxel (n = 326) Abiraterone acetate +  prednisone (n = 164) Enzalutamide (n = 111) Docetaxel (n = 58)` Cabazitaxel (n = 119)
Number of previous mCRPC treatments, n (%)
0 313 (96.6) 42 (79.2) 295 (90.5) 0 0 0 0
1 11 (3.4) 11 (20.8) 29 (8.9) 121 (73.8) 61 (55.0) 35 (60.3) 43 (36.1)
2 0 0 2 (0.6) 37 (22.6) 29 (26.1) 14 (24.1) 59 (49.6)
≥3 0 0 0 6 (3.6) 21 (18.9) 9 (15.5) 17 (14.3)
Median time to next therapy, days (95% CI)* 601 (467, NE) 503 (251, NE) 278 (259, 307) 428 (359, 514) 366 (296, NE) 322 (239, 404) 264 (240, 321)

*Kaplan–Meier estimates; patients with no next therapy were censored. Time to next therapy: time from start of 1st therapy to start of next therapy. NE, not estimable.

Conclusions

The results provide unique insights into treatment and outcomes in a large, real-world mCRPC patient population. These older patients have a high prevalence of comorbidities that are common in clinical practice but often not taken into account in the results of interventional clinical trials. Follow-up of these patients will allow assessment of treatment patterns and outcomes, and thereby contribute to optimising outcomes in subsets of mCRPC patients in clinical practice.

Clinical trial identification

ClinicalTrials.gov NCT02236637

Legal entity responsible for the study

Janssen Pharmaceutic

Funding

Janssen Pharmaceutic

Disclosure

S. Chowdhury: Consultant - Janssen Pharmaceuticals; Speakers' Bureau - Janssen Pharmaceuticals, Sanofi, Astellas Pharma Profession: Consultant medical oncologist. A.J. Birtle: Educational grants and advisory boards fees Janssen Sanofi Aventis Astellas, Roche. A. Bjartell: Consultant: EXINI Diagnostics, Speakers' Bureau: Astellas Pharma, Bayer Schering Pharma, Patents, Royalties, Other Intellectual Property: Glactone Pharma. L.A.;. Costa: Speakers' Bureau: Janssen. E. Kalinka-Warzocha: Honoraria, Consultant. Research Funding: Bristol-Myers Squibb, MSD, Roche, Novartis, Janssen, Angelini Pharmaceuticals. Travel, Accommodations, Expenses: MSD, Bristol-Myers Squibb, Roche.

G. Kramer: Honoraria – Janssen, Bayer, Astellas Pharma, Sanofi; Consultant – Janssen, Bayer, Astellas Pharma, GlaxoSmithKline, Sanofi, Ipsen, Takeda. Research Funding - Janssen, Bayer, Astellas Pharma

J.P. Maroto Rey: Consultant - Janssen Pharmaceuticals, Amgen, Bayer Schering Pharma, Novartis, Roche. Speakers' Bureau - Janssen Pharmaceuticals, Amgen, Bayer, Novartis, Roche.

N. Lumen: Honoraria – Lilly, Janssen, AstraZeneca; Consultant – Bayer; Research Funding – Janssen, Bayer, Astellas Pharma, Ipsen; Travel, Accommodations, Expenses – Bayer, Janssen, Ipsen, Astellas Pharma.

D. Spaeth: Honoraria – Roche, Sanofi, Amgen, Pfizer; Consultant – Roche, Sanofi, Amgen, Pfizer. Research Funding – Roche, Pierre Fabre; Other Relationship – Roche, Novartis, Pierre Fabre, Sanofi.

L. Antoni: Employment - Janssen Pharmaceutica.

E. Klumper: Consultant - Janssen Pharmaceuticals.

R. Wapenaar: Stock and Other Ownership Interests - Johnson & Johnson.

E. Lee: Stock and Other Ownership Interests – Janssen.

All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings